Wolff Wiese Magana LLC decreased its holdings in shares of Lantern Pharma Inc. (NASDAQ:LTRN – Get Rating) by 12.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,575 shares of the company’s stock after selling 4,580 shares during the quarter. Wolff Wiese Magana LLC’s holdings in Lantern Pharma were worth $180,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the business. Advisor Group Holdings Inc. boosted its holdings in Lantern Pharma by 92.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 5,331 shares of the company’s stock valued at $43,000 after acquiring an additional 2,561 shares during the last quarter. Envestnet Asset Management Inc. purchased a new stake in shares of Lantern Pharma during the fourth quarter worth about $84,000. Sanders Morris Harris LLC increased its position in shares of Lantern Pharma by 14.2% during the first quarter. Sanders Morris Harris LLC now owns 384,228 shares of the company’s stock worth $2,747,000 after acquiring an additional 47,803 shares during the last quarter. CM Management LLC purchased a new stake in shares of Lantern Pharma during the first quarter worth about $241,000. Finally, JPMorgan Chase & Co. increased its position in shares of Lantern Pharma by 52.7% during the first quarter. JPMorgan Chase & Co. now owns 8,018 shares of the company’s stock worth $57,000 after acquiring an additional 2,768 shares during the last quarter. Institutional investors and hedge funds own 13.10% of the company’s stock.
Lantern Pharma Stock Down 1.5 %
NASDAQ:LTRN traded down $0.07 during mid-day trading on Friday, reaching $4.68. The stock had a trading volume of 32 shares, compared to its average volume of 17,682. Lantern Pharma Inc. has a 1-year low of $4.67 and a 1-year high of $12.50. The stock’s 50 day simple moving average is $5.39 and its two-hundred day simple moving average is $5.85.
Lantern Pharma Profile
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.
- Get a free copy of the StockNews.com research report on Lantern Pharma (LTRN)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.